NASDAQ$GDRX
GoodRx Holdings Inc. · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
GoodRx reported its Q1 2024 financial results, showing revenue growth and progress towards becoming a 'Rule of 40' company.
GoodRx's Q1 2024 results showed positive momentum with revenue increasing by 8% to $197.9 million. The company is focused on reigniting growth and strengthening its business model, aiming to return to being a 'Rule of 40' company.
- Revenue and Adjusted Revenue reached $197.9 million, an 8% increase year-over-year.
- Net loss was $1.0 million, with a net loss margin of 0.5%.
- Adjusted EBITDA was $62.8 million, resulting in an Adjusted EBITDA Margin of 31.7%.
- The company exited the quarter with approximately 8 million consumers of prescription-related offerings.
Headline financials
Revenue & EPS history
GoodRx · Revenue · Quarterly
$198M
Revenue by segment
GoodRx · $175M total across 3 segments · Q3 2023
- Prescription Transactions$135M+3.2%77.6%
- Subscription$23.2M-12.5%13.3%
- Pharma Direct$15.9M-35.1%9.1%
Forward guidance
For Q2 2024, GoodRx anticipates revenue and Adjusted Revenue of approximately $200 million and an Adjusted EBITDA Margin in the low thirty-percent range. For the full year 2024, the company is raising its guidance for revenue and Adjusted Revenue to be between $800 million and $810 million and expects to achieve over $250 million of Adjusted EBITDA.
Tailwinds
- Revenue and Adjusted Revenue are expected to grow by approximately 5% year-over-year in Q2 2024.
- Full year revenue and Adjusted Revenue guidance raised to $800 million - $810 million.
- Adjusted EBITDA for the full year is expected to be over $250 million, up about 15% from 2023.
- Balance sheet and liquidity position remained strong in Q1 2024.
- Prioritizing cash conversion and disciplined capital deployment to support strategic priorities and accelerate value creation.
Headwinds
- Full year growth rate tempered by approximately $15 million of top-line impact associated with the de-prioritization of vitaCare.
- Anticipated sunset of the Kroger Savings Club is expected to impact revenue.
- Contra-revenue related to consumer incentives is expected to increase by almost $10 million this year.
- Change Healthcare outage expected to have a low-single-digit million-dollar impact on revenue.
- Approximately $25 million of top-line impact is absorbed in the full year $800 million to $810 million revenue and Adjusted Revenue guidance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-5.3%
Avg return
Earnings day
-8.5%
Avg return
5 days after
-5.0%
Avg return
30 days after
37%
10 / 27 earnings
Positive
+29.1%
Q4 2023
Best reaction
-37.4%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.4% | +10.5% | +3.5% | |
| Q4 2025 | -19.5% | -15.5% | -20.8% | |
| Q3 2025 | +1.8% | -6.1% | -16.9% | |
| Q1 2025 | +11.9% | +13.5% | +7.7% | |
| Q4 2024 | +1.8% | -4.5% | -8.0% | |
| Q3 2024 | -20.0% | -23.1% | -19.6% | |
| Q2 2024 | -16.3% | -20.2% | -10.5% | |
| Q1 2024 | -13.3% | -12.6% | +12.4% | |
| Q4 2023 | +29.1% | +17.6% | +9.7% | |
| Q3 2023 | -12.4% | -8.8% | +9.1% | |
| Q2 2023 | -5.6% | -14.1% | -29.3% | |
| Q1 2023 | +7.0% | +10.9% | +17.5% | |
| Q4 2022 | +5.6% | +13.6% | +14.2% | |
| Q3 2022 | -21.5% | +10.4% | +0.8% | |
| Q2 2022 | +10.5% | +4.1% | -12.6% | |
| Q1 2022 | -37.4% | -30.1% | -43.5% | |
| Q4 2021 | -36.3% | -39.2% | -27.9% | |
| Q3 2021 | -5.7% | -5.1% | -5.4% | |
| Q2 2021 | +20.0% | +13.3% | +37.1% | |
| Q1 2021 | +5.1% | +2.4% | +24.8% | |
| Q4 2018 | -10.5% | -14.2% | -7.9% | |
| Q2 2020 | -3.9% | -7.8% | -1.2% | |
| Q4 2020 | -3.9% | -7.8% | -1.2% | |
| Q1 2020 | -7.3% | -29.1% | -16.5% | |
| Q3 2019 | -7.3% | -29.1% | -16.5% | |
| Q3 2020 | -7.3% | -29.1% | -16.5% | |
| Q4 2019 | -7.3% | -29.1% | -16.5% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro